EHRLICHIA VACCINES AND IMMUNOGENIC COMPOSITIONS Russian patent published in 2024 - IPC A61K39/02 C07K16/12 C07K14/29 

FIELD: biotechnology.

SUBSTANCE: disclosed is an immunogenic composition containing: TRP140, TRP36 and TRP19 and a pharmaceutically acceptable excipient, wherein said pharmaceutically acceptable excipient contains an adjuvant, wherein said adjuvant contains a triterpenoid saponin, a sterol and an immunostimulating CpG-containing oligonucleotide. Described is a method for diagnosing exposure to or infection with Ehrlicia or E. canis, involving: obtaining a biological sample from a mammalian subject and testing the biological sample for immunoreactivity to TRP19, or TRP140 and TRP140, or TRP120, or TRP28; wherein the immunoreactivity to TRP120, TRP140 and / or TRP19 indicates that the subject has been exposed to or has been infected with Ehrlicia or E. canis. Described is a method of inducing an immune response in a mammal subject, involving administering to the subject a pharmaceutically relevant amount of the immunogenic composition.

EFFECT: invention extends the range of products for immunization against Ehrlichia canis.

26 cl, 6 tbl, 2 ex